Axsome Therapeutics Inc (AXSM)
99.56
-0.92
(-0.92%)
USD |
NASDAQ |
Dec 04, 16:00
99.40
-0.16
(-0.17%)
After-Hours: 20:00
Axsome Therapeutics Debt to Equity Ratio: 1.938 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.938 |
| June 30, 2024 | 1.744 |
| March 31, 2024 | 1.241 |
| December 31, 2023 | 0.9324 |
| September 30, 2023 | 0.6584 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.6342 |
| March 31, 2023 | 1.320 |
| December 31, 2022 | 0.8604 |
| September 30, 2022 | 0.5968 |
| June 30, 2022 | 6.149 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.5968
Minimum
Sep 2022
6.149
Maximum
Jun 2022
1.607
Average
1.086
Median
Debt to Equity Ratio Benchmarks
| Repligen Corp | 0.2586 |
| Pfizer Inc | 0.7219 |
| NovaBay Pharmaceuticals Inc | 0.0476 |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 561.46M |
| Total Liabilities (Quarterly) | 468.56M |
| Shareholders Equity (Quarterly) | 92.90M |
| Current Ratio | 2.442 |
| Net Debt Paydown Yield | -0.01% |